Spiroadamantyl 1,2,4-Trioxolane, 1,2,4-Trioxane, and 1,2,4-Trioxepane Pairs: Relationship Between Peroxide Bond Iron(II) Reactivity, Heme Alkylation Efficiency, and Antimalarial Activity by Wang, Xiaofang et al.
University of Nebraska at Omaha
DigitalCommons@UNO
Chemistry Faculty Publications Department of Chemistry
8-1-2009
Spiroadamantyl 1,2,4-Trioxolane, 1,2,4-Trioxane,
and 1,2,4-Trioxepane Pairs: Relationship Between
Peroxide Bond Iron(II) Reactivity, Heme
Alkylation Efficiency, and Antimalarial Activity
Xiaofang Wang
The University of Nebraska Medical Center, xiaofangwang@unmc.edu
Darren J. Creek
Monash University, Parkville, Victoria, Australia
Yuxiang Dong
The University of Nebraska Medical Center, ydong@unmc.edu
Jacques Chollet
Swiss Tropical Institute, Basel
Christian Scheurer
Swiss Tropical Institute, Basel
See next page for additional authors
Follow this and additional works at: https://digitalcommons.unomaha.edu/chemfacpub
Part of the Chemicals and Drugs Commons, and the Chemistry Commons
This Article is brought to you for free and open access by the Department
of Chemistry at DigitalCommons@UNO. It has been accepted for
inclusion in Chemistry Faculty Publications by an authorized administrator
of DigitalCommons@UNO. For more information, please contact
unodigitalcommons@unomaha.edu.
Recommended Citation
Wang, Xiaofang; Creek, Darren J.; Dong, Yuxiang; Chollet, Jacques; Scheurer, Christian; Wittlin, Sergio; Charman, Susan A.;
Dussault, Patrick H.; Wood, James K.; and Vennerstrom, Jonathan L., "Spiroadamantyl 1,2,4-Trioxolane, 1,2,4-Trioxane, and
1,2,4-Trioxepane Pairs: Relationship Between Peroxide Bond Iron(II) Reactivity, Heme Alkylation Efficiency, and Antimalarial
Activity" (2009). Chemistry Faculty Publications. 3.
https://digitalcommons.unomaha.edu/chemfacpub/3
Authors
Xiaofang Wang, Darren J. Creek, Yuxiang Dong, Jacques Chollet, Christian Scheurer, Sergio Wittlin, Susan A.
Charman, Patrick H. Dussault, James K. Wood, and Jonathan L. Vennerstrom
This article is available at DigitalCommons@UNO: https://digitalcommons.unomaha.edu/chemfacpub/3
University of Nebraska Omaha
DigitalCommons@UNO
Chemistry Faculty Publications and Presentations Department of Chemistry
8-1-2009
Spiroadamantyl 1,2,4-trioxolane, 1,2,4-trioxane, and
1,2,4-trioxepane pairs: Relationship between
peroxide bond iron(II) reactivity, heme alkylation
efficiency, and antimalarial activity
Xiaofang Wang
University of Nebraska Medical Center
Darren J. Creek




University of Nebraska Medical Center
Jacques Chollet
Swiss Tropical Institute, Basel
See next page for additional authors
This Article is brought to you for free and open access by the Department of Chemistry at DigitalCommons@UNO. It has been accepted for inclusion
in Chemistry Faculty Publications and Presentations by an authorized administrator of DigitalCommons@UNO. For more information, please contact
mmaring@unomaha.edu.
Recommended Citation
Wang, Xiaofang; Creek, Darren J.; Schiaffo, Charles E.; Dong, Yuxiang; Chollet, Jacques; Scheurer, Christian; Wittlin, Segio;
Charman, Susan A.; Dussault, Patrick; Wood, James K.; and Vennerstrom, Jonathan L., "Spiroadamantyl 1,2,4-trioxolane,
1,2,4-trioxane, and 1,2,4-trioxepane pairs: Relationship between peroxide bond iron(II) reactivity, heme alkylation efficiency, and
antimalarial activity" (2009). Chemistry Faculty Publications and Presentations. Paper 1.
http://digitalcommons.unomaha.edu/chmfacpub/1
Authors
Xiaofang Wang, Darren J. Creek, Charles E. Schiaffo, Yuxiang Dong, Jacques Chollet, Christian Scheurer,
Segio Wittlin, Susan A. Charman, Patrick Dussault, James K. Wood, and Jonathan L. Vennerstrom
This article is available at DigitalCommons@UNO: http://digitalcommons.unomaha.edu/chmfacpub/1
The semisynthetic artemisinins rapidly reduce parasite bur-
den and are particularly effective when used in a 3-day ar-
temisinin combination treatment (ACT) regimen.1 One hy-
pothesis2–4 that accounts for the antimalarial specificity of 
artemisinin5 is that the peroxide bond undergoes reductive ac-
tivation by heme released by parasite hemoglobin digestion to 
produce carbon-centered free radicals or carbocations that al-
kylate heme6 or parasite proteins. Although the 1,2,4-trioxane 
heterocycle in artemisinin (Figure 1) is the critical pharmaco-
phore, its presence alone7 is insufficient for high antimalarial 
activity as most synthetic 1,2,4-trioxanes are less active than 
artemisinin.8 The discovery9 of ozonide (1,2,4-trioxolane) drug 
development candidate OZ277 (arterolane) (Figure 1), now en-
tering Phase III clinical trials in the form of an arterolane ma-
leate + piperaquine phosphate combination, prompted us 
to investigate a set of structurally related 1,2,4-trioxolanes 1, 
1,2,4-trioxanes 2, and 1,2,4-trioxepanes 310 (Figure 2) to better 
understand the relationship between peroxide bond iron(II) 
reactivity and antimalarial activity for these homologous per-
oxide heterocycles.
Trioxolanes 1b11 and 1c were obtained by Griesbaum 
coozonolysis12 of the corresponding oxime ether/ketone13–14 
pairs 4/5 and 6/7 in low yields (Scheme 1). Trioxolane 1a was 
similarly obtained as previously described.15
Trioxanes 2b and 2c were prepared as shown in Scheme 2. 
In the presence of catalytic p-toluenesulfonic acid (PTSA), 2b 
was readily formed by condensation of β-hydroperoxy alco-
hol 816 with 5. Attempts to perform the corresponding reac-
tion of β-hydroperoxy alcohol 916 with 5 provided only small 
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Abstract
These data suggest that iron(II) reactivity for a set of homologous spiroadamantyl 1,2,4-trioxolane, 1,2,4-trioxane, and 
1,2,4-trioxepane peroxide heterocycles is a necessary, but insufficient, property of animalarial peroxides. Heme al-
kylation efficiency appears to give a more accurate prediction of antimalarial activity than FeSO4-mediated reaction 
rates, suggesting that antimalarial activity is not merely dependent on peroxide bond cleavage, but also on the ability 
of reactive intermediates to alkylate heme or other proximal targets.
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Figure 1. Artemisinin and OZ277. 
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of decomposition products. Characterization of the reaction 
products indicated that β-hydroperoxy alcohol 9 underwent 
acid-catalyzed O–O bond (pathway I) and C–O bond (path-
way II) heterolysis followed by rearrangement. Formation of 
ketone 7 (pathway I) can be rationalized by a Grob-type frag-
mentation or by migration of the hydroxymethyl group.17 
This contrasts with the phenyl migration seen in the acid-cat-
alyzed decomposition of cumene hydroperoxide to form phe-
nol and acetone.18 Aldehyde 11 may arise from the formation 
and rearrangement of a relatively stable benzylic tertiary car-
bocation in the transition state for fragmentation, with the 
co-generated hydrogen peroxide producing lactone 12 via an 
acid-catalyzed Baeyer–Villiger oxidation of adamantanone 
Thus, acid-catalyzed heterolytic peroxide bond fragmentation 
(pathway II) was the dominant reaction course for 9. There-
fore, we tried protecting the hydroperoxide functional group 
of 9 to suppress the fragmentation.19 Treatment of 9 with N,O-
bis-(trimethylsilyl)acetamide (BSA) in CH2Cl2 gave the corre-
sponding bis(trimethylsilylated) product 10 in high yield. Sub-
sequent condensation of 10 with 5 in the presence of 10–20% 
CSA in CH2Cl2 afforded the desired 2c (Scheme 2). Trioxane 2a 
was prepared as previously described.20
Trioxepanes 3a and 3b were prepared via parallel routes 
(Scheme 3) beginning with alcohol 1321 and cinnamyl alcohol 
(14). The corresponding acetates (15, 16) underwent successive 
Co-mediated dioxygenation22 and chemoselective reduction to 
furnish triethylsilyl peroxyalcohols 17 and 18.23 The peroxyal-
cohols underwent HF-mediated condensation with ketone 5 to 
produce 3a and 3b.
In vitro and in vivo antimalarial activities9 (Table 1) were 
measured using the chloroquine-resistant K1 and chloroquine-
sensitive NF54 strains of Plasmodium falciparum and Plasmo-
dium berghei-infected mice. Several observations arise from the 
antimalarial data. First, trioxolane 1b was more than two or-
ders of magnitude less potent than trioxolanes 1a and 1c. Be-
cause it has a α-H atom, 1b may lack the necessary chemical 
Scheme 3. 
Figure 2. Trioxolanes 1, trioxanes 2, and trioxepanes 3. 
Scheme 1. 
Scheme 2. 
















stability24 required for antimalarial activity. This contrasts 
with the good antimalarial activity of the corresponding and 
presumably more chemically stable trioxane 2b. Trioxanes 2a 
and 2c were less potent than the corresponding trioxolanes 1a 
and 1c; neither 2a nor 2c had any activity in vivo. The less ac-
cessible peroxide bond in the trioxane vs trioxolane heterocy-
cle20 may explain why trioxanes 2a and 2c are less active than 
their trioxolane chemical cousins 1a and 1c. Similarly, the com-
plete lack of activity of trioxepanes 3a and 3b may arise from 
peroxide bonds that are too sterically hindered (vide infra). 
These data suggest that antimalarial activity for these spiroa-
damantyl trioxolanes, trioxanes, and trioxepanes depends on a 
finely tuned balance between peroxide bond shielding and ac-
cessibility. To provide mechanistic insight into this hypothe-
sis, we examined the reactivity of several of these compounds 
with iron(II) in the form of FeSO4 and heme.
The reactivity of 1–3 with inorganic ferrous iron was de-
termined using previously established standardized condi-
tions.25 In these experiments, pseudo-first order reaction rate 
constants for 1b, 2a, 2b, 3a, and 3b (0.03 mM) with FeSO4 
(3 mM) in 50% acetonitrile/water at 37 °C under an argon 
atmosphere were determined. These data (n = 3) were cor-
rected for non-specific degradation in iron-free controls. Un-
der these experimental conditions, the previously determined 
pseudo-first order rate constants (k) for 1a and artemisinin 
were 0.41 ± 0.02 h−126 and 0.054 ± 0.006 h−1.25 The weakly ac-
tive 1b reacted considerably more rapidly (k = 1.77 ± 0.06 h−1) 
with iron(II) than did 1a confirming our previous observa-
tions26–27 that chemically reactive peroxides do not necessarily 
possess high antimalarial activities. Trioxane 2b reacted with 
iron(II) at a rate (k = 0.12 ± 0.03 h−1) between that of 1a and ar-
temisinin, whereas trioxepane 3b reacted much more slowly 
(k = 0.021 ± 0.006 h−1), and neither 2a nor 3a underwent statis-
tically significant degradation over the 24 h time course stud-
ied (k = 0.011 ± 0.013 h−1 and 0.017 ± 0.012 h−1, respectively).
As has been previously demonstrated for 1a versus 2a,20 
the difference in iron-mediated reactivity between 1a and 3a 
can be explained by considering peroxide bond accessibility 
of the more reactive equatorial peroxide bond conformers28 
as determined by molecular modeling (Spartan’08, Wavefunc-
tion, Inc.). As shown in Figure 3, the peroxide bond LUMO in 
1a is easily accessible from the cyclohexane side, whereas the 
peroxide bond LUMO in 3a is not accessible from either direc-
tion, consistent with the low reactivity of 3a with iron(II). The 
greater steric crowding in 3a is due to the methylene groups 
of the trioxepane ring decreasing the angle between the ad-
amantane and cyclohexane rings. This lack of iron-mediated 
reactivity for trioxepane 3a is consistent with its lack of anti-
malarial activity; similar arguments have been put forth to ex-
plain the low antimalarial activity of other sterically congested 
1,2,4-trioxepanes.29
We have previously shown30 a good correlation between in 
vitro antimalarial activity and heme alkylation efficiency for a 
series of 22 trioxolanes. We measured the efficiency of heme 
alkylation for these trioxolanes, trioxanes and trioxepanes us-
ing these same experimental conditions.30 Significant heme al-
kylation was observed within 30 s for the active 1c (67 ± 2%) 
and moderately active 2b (55 ± 4%), and to a slightly lesser 
extent for the less active 1b (50 ± 1%) and 2a (45 ± 1%); how-
ever the extent of heme alkylation by these compounds was 
far lower than previously reported for the highly active tri-
oxolanes 1a (86 ± 0.2%) and OZ277 (83 ± 2%).30 Trioxepanes 
3a and 3b mediated very little heme alkylation (25 ± 1% and 
1 ± 0.4%), in agreement with their lack of antimalarial activity. 
The investigation of heme alkylation appears to give a more 
accurate prediction of antimalarial activity than investigation 
of iron-mediated reaction rates, suggesting that antimalar-
ial activity is not merely dependant on peroxide bond cleav-
age, but also on the ability of reactive intermediates to alkylate 
heme or other proximal targets. This further supports a likely 
role for heme alkylation in the antimalarial mechanism of ac-
tion of peroxide antimalarials.6
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